Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 27, Issue 1, 2013, Pages 37-48

  Tomé Carneiro, João ^a   Gonzálvez, Manuel ^b   Larrosa, Mar ^a   Yáñez Gascón, María J ^a   García Almagro, Francisco J ^b   Ruiz Ros, José A ^b   Tomás Barberán, Francisco A ^a   García Conesa, María T ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Adiponectin; Cardiovascular; Clinical trial; Coronary artery disease; Plasminogen activator inhibitor type 1 (PAI 1); Resveratrol

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ADIPONECTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GRAPE EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; PLANT EXTRACT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C JUN; RESVERATROL; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DOWN REGULATION; FEMALE; GENE FUNCTION; GRAPE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DOWN-REGULATION; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLANT EXTRACTS; RESEARCH DESIGN; STILBENES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VITIS;

EID: 84873060656     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6427-8     Document Type: Article

References (49)

1. World Health Organization. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva: WHO Press; 2007.
2. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54-63.
3. Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA. 2003;100:6658-63.
4. Lin Z, Kumar A, SenBanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96:e48-57.
5. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31:777-83.
6. Smith Jr SC, Benjamin EJ, Bonow RO, World Heart Federation and the Preventive Cardiovascular Nurses Association, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432-46.
7. Kazemian P, Kazemi-Bajestani SM, Alherbish A, Steed J, Oudit GY. The use of ω-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc Drugs Ther. 2012;26:311-20.
8. Pauwels EK. The protective effect of the mediterranean diet: focus on cancer and cardiovascular risk. Med Princ Pract. 2011;20:103-11.
9. Chen YR, Yi FF, Li XY, Wang CY, Chen L. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther. 2009;23:449-58.
10. Akar F, Pektas MB, Tufan C, et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther. 2011;25:119-31.
11. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6:e19881.
12. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann NY Acad Sci. 2011;1215:161-9.
13. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients from primary prevention of cardiovascular disease. A triple-blind, 6-months follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res. 2012;56:810-21.
14. Cantos E, Espín JC, Tomás-Barberán FA. Postharvest induction modeling method using UV irradiation pulses for obtaining resveratrol-enriched table grapes: a new 'functional' fruit? J Agric Food Chem. 2001;49:5052-8.
15. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110:356-63.
16. Azorín-Ortuño M, Yáñez-Gascón MJ, Pallarés FJ, et al. A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet. J Agric Food Chem. 2012;60:5609-20.
17. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339:1523-6.
18. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventós RM, et al. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. Br J Nutr. 2008;100:188-96.
19. Stervbo U, Vang O, Bonnesen C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 2007;101:449-57.
20. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci. 2008;114:361-74.
21. Karastergiou K, Evans I, Ogston N, et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30:1340-6.
22. Cavusoglu E, Ruwende C, Chopra V, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27:2300-9.
23. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J. 2006;27:2266-8.
24. Kunita E, Yamamoto H, Kitagawa T, et al. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J. 2012;76:1687-96.
25. Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;90:528-33.
26. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol. 2011;57:761-70.
27. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792-801.
28. Belalcazar LM, Ballantyne CM, Lang W, Look Action for Health in Diabetes Research Group, et al. Look action for health in diabetes research group. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the Look AHEAD study. Arterioscler Thromb Vasc Biol. 2011;31:1689-95.
29. Mertens I, Ballaux D, Funahashi T, et al. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost. 2005;94:1190-5.
30. Maruyoshi H, Kojima S, Funahashi T, et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost. 2004;91:1026-30.
31. Chan KC, Chou HH, Huang CN, Chou MC. Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clin Cardiol. 2008;31:253-8.
32. Kaba NK, Francis CW, Moss AJ, et al. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost. 2004;2:718-25.
33. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77:1053-63.
34. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes. 2010;34:1546-53.
35. Petrowski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann NY Acad Sci. 2011;1215:22-33.
36. Azorín-Ortuño M, Yáñez-Gascón MJ, González-Sarrías A, et al. Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention. J Nutr Biochem. 2012;23:829-37.
37. Brasnyó P, Molnár GA, Mohás M. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383-9.
38. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537-41.
39. Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179-87.
40. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
41. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
42. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-5.
43. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 2003;9:549-57.
44. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol. 1998;63:139-52.
45. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem. 2001;276:13505-8.
46. Azorín-Ortuño M, Yáñez-Gascón MJ, Vallejo F, et al. Metabolites and tissue distribution of resveratrol in the pig. Mol Nutr Food Res. 2011;55:1154-68.
47. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-206.
48. Moreno-Palanco MA, Ibáñez-Sanz P, Ciria-de Pablo C, et al. Impact of comprehensive and intensive treatment of risk factors concerning cardiovascular mortality in secondary prevention: MIRVAS study. Rev Esp Cardiol. 2011;64:179-85.
49. Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33:2831-40.